Portal de Periódicos da CAPES

1540P Ripretinib as ≥4th-line treatment in patients with advanced gastrointestinal stromal tumor: Long-term update from the phase III INVICTUS study

2021; Elsevier BV; Volume: 32; Linguagem: Inglês

10.1016/j.annonc.2021.08.870

1569-8041

Margaret von Mehren, Michael C. Heinrich, Suzanne George, John Zalcberg, Sebastian Bauer, Hans Gelderblom, Patrick Schöffski, César Serrano, Robin L. Jones, Steven Attia, Gina Z. D’Amato, Ping Chi, Peter Reichardt, Julie Nicole Meade, V. Reichert, Kelvin Shi, Rodrigo Ruiz‐Soto, Jean‐Yves Blay,

Metastasis and carcinoma case studies

Ripretinib is an approved switch-control tyrosine kinase inhibitor (TKI) that broadly inhibits mutant KIT and PDGFRA kinase signaling. In INVICTUS, a randomized, double-blind, placebo-controlled trial in ≥4th-line advanced GIST, ripretinib compared with placebo (PBO) significantly improved median progression-free survival (mPFS; 6.3 vs 1.0 months), reducing the risk of disease progression or death by 85%, and showed a clinically meaningful improvement in median overall survival (mOS; 15.1 vs 6.6 months); data as of May 31, 2019 (ESMO 2019).